This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koelle, D. M.
Right arrow Articles by Corey, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koelle, D. M.
Right arrow Articles by Corey, L.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Herpes Simplex

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2003, p. 96-113, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.96-113.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research

David M. Koelle1,2,3,4,5* and Lawrence Corey1,3,4

Departments of Medicine,1 Pathobiology,2 Laboratory Medicine, University of Washington, Seattle, Washington 98195,3 Fred Hutchinson Cancer Research Center, Seattle, Washington 98109,4 Virginia Mason Research Center, Seattle, Washington 981015

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) cause prevalent, chronic infections that have serious outcomes in some individuals. Neonatal herpes may occur when the infant traverses the cervix during maternal genital herpes. Genital herpes is a major risk factor for human immunodeficiency virus type 1 transmission. Considerable efforts have been made to design and test vaccines for HSV, focusing on genital infection with HSV-2. Several protein subunit vaccines based on HSV-2 envelope glycoproteins have reached advanced-phase clinical trials. These antigens were chosen because they are the targets of neutralizing-antibody responses and because they elicit cellular immunity. Encouraging results have been reported in studies of treatment of HSV-seronegative women with a vaccine consisting of truncated glycoprotein D of HSV-2 and a novel adjuvant. Because most sexual HSV transmission occurs during asymptomatic shedding, it is important to evaluate the impact of vaccination on HSV-2 infection, clinically apparent genital herpes, and HSV shedding among vaccine recipients who acquire infection. There are several other attractive formats, including subunit vaccines that target cellular immune responses, live attenuated virus strains, and mutant strains that undergo incomplete lytic replication. HSV vaccines have also been evaluated for the immunotherapy of established HSV infection.

* Corresponding author. Mailing address: Harborview Medical Center Mail Stop 359690, 325 Ninth Ave., Seattle, WA 98104. Phone: (206) 341-5207. Fax: (206) 341-5203. E-mail: viralimm{at}u.washington.edu.

Clinical Microbiology Reviews, January 2003, p. 96-113, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.96-113.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kwant-Mitchell, A., Ashkar, A. A., Rosenthal, K. L. (2009). Mucosal Innate and Adaptive Immune Responses against Herpes Simplex Virus Type 2 in a Humanized Mouse Model. J. Virol. 83: 10664-10676 [Abstract] [Full Text]  
  • Muller, W. J., Dong, L., Vilalta, A., Byrd, B., Wilhelm, K. M., McClurkan, C. L., Margalith, M., Liu, C., Kaslow, D., Sidney, J., Sette, A., Koelle, D. M. (2009). Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 90: 1153-1163 [Abstract] [Full Text]  
  • Bernstein, D. I., Cardin, R. D., Bravo, F. J., Strasser, J. E., Farley, N., Chalk, C., Lay, M., Fairman, J. (2009). Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines. CVI 16: 699-705 [Abstract] [Full Text]  
  • Jamali, A., Mahdavi, M., Hassan, Z. M., Sabahi, F., Farsani, M. J., Bamdad, T., Soleimanjahi, H., Motazakker, M., Shahabi, S. (2009). A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol 21: 217-225 [Abstract] [Full Text]  
  • Grubor-Bauk, B., Arthur, J. L., Mayrhofer, G. (2008). Importance of NKT Cells in Resistance to Herpes Simplex Virus, Fate of Virus-Infected Neurons, and Level of Latency in Mice. J. Virol. 82: 11073-11083 [Abstract] [Full Text]  
  • Goldmeier, D., Garvey, L., Barton, S. (2008). Does chronic stress lead to increased rates of recurrences of genital herpes - a review of the psychoneuroimmunological evidence?. Int J STD AIDS 19: 359-362 [Abstract] [Full Text]  
  • Koelle, D. M., Magaret, A., McClurkan, C. L., Remington, M. L., Warren, T., Teofilovici, F., Wald, A. (2008). Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected Subjects. CVI 15: 773-782 [Abstract] [Full Text]  
  • Hoshino, Y., Pesnicak, L., Cohen, J. I., Straus, S. E. (2007). Rates of Reactivation of Latent Herpes Simplex Virus from Mouse Trigeminal Ganglia Ex Vivo Correlate Directly with Viral Load and Inversely with Number of Infiltrating CD8+ T Cells. J. Virol. 81: 8157-8164 [Abstract] [Full Text]  
  • Zhu, J., Koelle, D. M., Cao, J., Vazquez, J., Huang, M. L., Hladik, F., Wald, A., Corey, L. (2007). Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. JEM 204: 595-603 [Abstract] [Full Text]  
  • Verjans, G. M. G. M., Hintzen, R. Q., van Dun, J. M., Poot, A., Milikan, J. C., Laman, J. D., Langerak, A. W., Kinchington, P. R., Osterhaus, A. D. M. E. (2007). Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 104: 3496-3501 [Abstract] [Full Text]  
  • Raftery, M. J., Winau, F., Kaufmann, S. H. E., Schaible, U. E., Schonrich, G. (2006). CD1 Antigen Presentation by Human Dendritic Cells as a Target for Herpes Simplex Virus Immune Evasion. J. Immunol. 177: 6207-6214 [Abstract] [Full Text]  
  • Tengvall, S., Lundqvist, A., Eisenberg, R. J., Cohen, G. H., Harandi, A. M. (2006). Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes.. J. Virol. 80: 5283-5291 [Abstract] [Full Text]  
  • Hosken, N., McGowan, P., Meier, A., Koelle, D. M., Sleath, P., Wagener, F., Elliott, M., Grabstein, K., Posavad, C., Corey, L. (2006). Diversity of the CD8+ T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes.. J. Virol. 80: 5509-5515 [Abstract] [Full Text]  
  • Koelle, D. M., Huang, J., Hensel, M. T., McClurkan, C. L. (2006). Innate Immune Responses to Herpes Simplex Virus Type 2 Influence Skin Homing Molecule Expression by Memory CD4+ Lymphocytes. J. Virol. 80: 2863-2872 [Abstract] [Full Text]  
  • Zhang, X., Issagholian, A., Berg, E. A., Fishman, J. B., Nesburn, A. B., BenMohamed, L. (2005). Th-Cytotoxic T-Lymphocyte Chimeric Epitopes Extended by N{varepsilon}-Palmitoyl Lysines Induce Herpes Simplex Virus Type 1-Specific Effector CD8+ Tc1 Responses and Protect against Ocular Infection. J. Virol. 79: 15289-15301 [Abstract] [Full Text]  
  • Lauterbach, H., Ried, C., Epstein, A. L., Marconi, P., Brocker, T. (2005). Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity. J. Gen. Virol. 86: 2401-2410 [Abstract] [Full Text]  
  • Perez-Romero, P., Fuller, A. O. (2005). The C Terminus of the B5 Receptor for Herpes Simplex Virus Contains a Functional Region Important for Infection. J. Virol. 79: 7431-7437 [Abstract] [Full Text]  
  • Gillgrass, A. E., Fernandez, S. A., Rosenthal, K. L., Kaushic, C. (2005). Estradiol Regulates Susceptibility following Primary Exposure to Genital Herpes Simplex Virus Type 2, while Progesterone Induces Inflammation. J. Virol. 79: 3107-3116 [Abstract] [Full Text]  
  • Gillgrass, A. E., Tang, V. A., Towarnicki, K. M., Rosenthal, K. L., Kaushic, C. (2005). Protection against Genital Herpes Infection in Mice Immunized under Different Hormonal Conditions Correlates with Induction of Vagina-Associated Lymphoid Tissue. J. Virol. 79: 3117-3126 [Abstract] [Full Text]  
  • Hoshino, Y., Dalai, S. K., Wang, K., Pesnicak, L., Lau, T. Y., Knipe, D. M., Cohen, J. I., Straus, S. E. (2005). Comparative Efficacy and Immunogenicity of Replication-Defective, Recombinant Glycoprotein, and DNA Vaccines for Herpes Simplex Virus 2 Infections in Mice and Guinea Pigs. J. Virol. 79: 410-418 [Abstract] [Full Text]  
  • Minagawa, H., Hashimoto, K., Yanagi, Y. (2004). Absence of tumour necrosis factor facilitates primary and recurrent herpes simplex virus-1 infections. J. Gen. Virol. 85: 343-347 [Abstract] [Full Text]  
  • Herbst, M. M., Pyles, R. B. (2003). Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother 52: 887-889 [Full Text]  
  • BenMohamed, L., Bertrand, G., McNamara, C. D., Gras-Masse, H., Hammer, J., Wechsler, S. L., Nesburn, A. B. (2003). Identification of Novel Immunodominant CD4+ Th1-Type T-Cell Peptide Epitopes from Herpes Simplex Virus Glycoprotein D That Confer Protective Immunity. J. Virol. 77: 9463-9473 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»